Neoadjuvant erlotinib and surgical resection of a stage IIIA papillary adenocarcinoma of the lung with an L861Q activating EGFR mutation

Current Oncology

Volumn 19, Issue 3, 2012, Pages

  Ong, M ^a   Kwan, K ^a   Kamel Reid, S ^b   Vincent, Mark ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

EGFR; Erlotinib; Neoadjuvant; Papillary adenocarcinoma

Indexed keywords

AFATINIB; ALKALINE PHOSPHATASE; CARBOPLATIN; CYTOKERATIN 7; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GLUTAMINE; LACTATE DEHYDROGENASE; LEUCINE; THYROID TRANSCRIPTION FACTOR 1;

AGED; ANEMIA; ARTICLE; BLOOD ANALYSIS; CANCER STAGING; CASE REPORT; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY SKIN; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FATIGUE; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; PAPILLARY CARCINOMA; PHYSICAL EXAMINATION; POINT MUTATION; POSITRON EMISSION TOMOGRAPHY; RECEPTOR GENE; THORAX RADIOGRAPHY; THROMBOCYTOSIS; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 84930477907     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.908     Document Type: Article

References (24)

1. Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959;2:257-66.
2. Ninomiya H, Hiramatsu M, Inamura K, et al. Correlation between morphology and EGFR mutations in lung adenocarcinomas. Significance of the micropapillary pattern and the hobnail cell type. Lung Cancer 2009;63:235-40.
3. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 who mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008;32:810-27.
4. van Meerbeeck JP, Kramer GW, Van Schil PE, et al. on behalf of the European Organisation for Research and Treatment of Cancer-Lung Cancer Group. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage iiia-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007;99:442-50.
5. Felip E, Rosell R, Massuti B, et al. The natch trial: observations on the neoadjuvant arm [abstract 7578]. J Clin Oncol 2007;25:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID= 47&abstractID=32833; cited April 6, 2012]
6. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage iii non-small-cell lung cancer: a phase iii randomised controlled trial. Lancet 2009;374:379-86.
7. Paul S, Mirza F, Port JL, et al. Survival of patients with clinical stage iiia non-small cell lung cancer after induction therapy: age, mediastinal downstaging, and extent of pulmonary resection as independent predictors. J Thorac Cardiovasc Surg 2011;141:48-58.
8. Kappers I, Klomp HM, Burgers JA, Van Zandwijk N, Haas RL, van Pel R. Neoadjuvant (induction) erlotinib response in stage iiia non-small-cell lung cancer. J Clin Oncol 2008;26:4205-7.
9. Takamochi K, Suzuki K, Sugimura H, et al. Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation. Lung Cancer 2007;58:149-55.
10. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
11. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
12. Makimoto Y, Nabeshima K, Iwasaki H, et al. Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (≤20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi's type C tumours). Histopathology 2005;46:677-84.
13. Miyoshi T, Satoh Y, Okumura S, et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol 2003;27:101-9.
14. Nassar H. Carcinomas with micropapillary morphology: clinical significance and current concepts. Adv Anat Pathol 2004;11:297-303.
15. Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 2006;12:1647-53.
16. Chen YR, Fu YN, Lin CH, et al. Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene 2006;25:1205-15.
17. Kim DW, Lee SH, Lee JS, et al. A multicenter phase ii study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. Lung Cancer 2011;71:65-9.
18. Costa DB, Nguyen KS, Cho BC, et al. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 2008;14:7060-7.
19. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-9.
20. Kancha RK, Peschel C, Duyster J. The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors. J Thorac Oncol 2011;6:387-92.
21. Hirano S, Sano K, Morii S, et al. A case of lung adenocarcinoma successfully treated with dose-reescalated gefitinib after resistance was acquired [Japanese]. Gan To Kagaku Ryoho 2009;36:1333-6.
22. Schneider CP, Heigener D, Schott-von-Römer K, et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from German centers in the trust study. J Thorac Oncol 2008;3:1446-53.
23. Sholl LM, Yeap BY, Iafrate AJ, et al. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res 2009;69:8341-8.
24. Goss GD, Lorimer I, Tsao MS, et al. A phase iii randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinib in completely resected stage ib-iiia non-small cell lung cancer (nsclc): ncic ctg br.19 [abstract LBA7005]. J Clin Oncol 2010;28:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstract ID=48314; cited: April 6, 2012]